Hideya Kamei

Hideya Kamei

Auto-generated profile, based on publicly available information

Hideya Kamei

Department of Transplantation Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
HKHideya Kamei
Hideya Kamei
FOFumitaka Oike
Fumitaka Oike
YFYasuhiro Fujimoto
Yasuhiro Fujimoto
HYHidekazu Yamamoto
Hidekazu Yamamoto
KTKoichi Tanaka
Koichi Tanaka
TKTetsuya Kiuchi
Tetsuya Kiuchi

1 September 2007 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
HKHideya Kamei
Hideya Kamei
YFYasuhiro Fujimoto
Yasuhiro Fujimoto
SNShunji Nagai
Shunji Nagai
RSRyuichiro Suda
Ryuichiro Suda
HYHidekazu Yamamoto
Hidekazu Yamamoto
TKTetsuya Kiuchi
Tetsuya Kiuchi

27 October 2015 in Transplantation Proceedings
Verified
Journal Article
Closed access
HKH. Kamei
H. Kamei
HIH. Imai
H. Imai
YOY. Onishi
Y. Onishi
MIM. Ishihara
M. Ishihara
MNM. Nakamura
M. Nakamura
YOY. Ogura
Y. Ogura

1 December 2013 in Journal of Surgical Research
Verified
Journal Article
Closed access
HKHideya Kamei
Hideya Kamei
MAMamoun Al-Basheer
Mamoun Al-Basheer
JSJeffrey Shum
Jeffrey Shum
MBMichael Bloch
Michael Bloch
WWWilliam Wall
William Wall
DQDouglas Quan
Douglas Quan

4 July 2017 in Annals of Transplantation
Verified
Journal Article
Closed access
PDF file
HKHideya Kamei
Hideya Kamei
YOYasuharu Onishi
Yasuharu Onishi
NKNobuhiko Kurata
Nobuhiko Kurata
MIMasatoshi Ishigami
Masatoshi Ishigami
YOYasuhiro Ogura
Yasuhiro Ogura
We reported a strategy of thrombophilia testing-guided venous thromboembolic events (VTE) prophylaxis for living donors of liver transplantation in 2011. The aim of the present study was to evaluate the safety and efficacy of this protocol for VTE prophylaxis. Thrombophilia testing, including protein S (PS), protein C (PC), antithrombin (AT) III, and anti-phospholipid antibody (APLA), was performed in 306 living donor candidates between July 2005 and June 2016. Donors who met any of the criteria of PS <60%, PC <64%, AT-III <70%, and positive APLA were classified into the borderline group and received continuous venous infusion of heparin immediately after surgery, in addition to use of elastic stockings and intermittent pneumatic compression (IPC) until patients were ambulatory. Other donors who were classified into the normal group used elastic stockings and IPC with no anticoagulants. The efficacy and safety endpoints were VTE occurrence and bleeding events, respectively. PS was considerably decreased in 3 candidates and PC was considerably reduced in 1 candidate, and they were excluded for high risk of VTE. Seventeen candidates in the borderline group and 137 in the normal group underwent donor surgery. One donor in the borderline group developed a wound hematoma. Postoperative complications were similar between the 2 groups. None of the donors in either group developed VTE. Thrombophilia testing-guided VTE prophylaxis is safe and may contribute to reduced VTE risk in donors, although further investigations are warranted to assess the necessity of thrombophilia testing prior to surgery among living donors.

17 December 2019 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
SOSatoshi Ogiso
Satoshi Ogiso
HKHideya Kamei
Hideya Kamei
YOYasuharu Onishi
Yasuharu Onishi
NKNobuhiko Kurata
Nobuhiko Kurata
KJKanta Jobara
Kanta Jobara
YOYasuhiro Ogura
Yasuhiro Ogura